We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Pharmacological ascorbate as a novel therapeutic strategy to enhance cancer immunotherapy.
- Authors
Zaher, Amira; Stephens, Laura M.; Miller, Ann M.; Hartwig, Stacey M.; Stolwijk, Jeffrey M.; Petronek, Michael S.; Zacharias, Zeb R.; Wadas, Thaddeus J.; Monga, Varun; Cullen, Joseph J.; Furqan, Muhammad; Houtman, Jon C. D.; Varga, Steven M.; Spitz, Douglas R.; Allen, Bryan G.
- Abstract
Pharmacological ascorbate (i.e., intravenous infusions of vitamin C reaching ~ 20 mM in plasma) is under active investigation as an adjuvant to standard of care anti-cancer treatments due to its dual redox roles as an antioxidant in normal tissues and as a prooxidant in malignant tissues. Immune checkpoint inhibitors (ICIs) are highly promising therapies for many cancer patients but face several challenges including low response rates, primary or acquired resistance, and toxicity. Ascorbate modulates both innate and adaptive immune functions and plays a key role in maintaining the balance between pro and anti-inflammatory states. Furthermore, the success of pharmacological ascorbate as a radiosensitizer and a chemosensitizer in preclinical studies and early phase clinical trials suggests that it may also enhance the efficacy and expand the benefits of ICIs.
- Subjects
IMMUNE checkpoint inhibitors; IMMUNOTHERAPY; INTRAVENOUS therapy; VITAMIN C; CANCER treatment
- Publication
Frontiers in Immunology, 2022, Vol 13, p1
- ISSN
1664-3224
- Publication type
Article
- DOI
10.3389/fimmu.2022.989000